Side Effects of daclizumab injection: A Synthesis of Findings from 10 Studies

  1. Home
  2. Side Effects of daclizumab injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of daclizumab injection: A Synthesis of Findings from 10 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of daclizumab injection: A Synthesis of Findings from 10 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Daclizumab is a humanized monoclonal antibody that targets the interleukin-2 (IL-2) receptor, preventing the activation of immune cells. It has been approved for the treatment of relapsing forms of multiple sclerosis (MS), but it has also been associated with severe adverse effects. 9 、 8 、 10 、 2 Studies have shown that daclizumab can be effective in controlling uveitis, a serious eye inflammation. 8 However, some studies have reported serious and potentially life-threatening side effects, including severe inflammatory brain disease and drug reaction with eosinophilia and systemic symptoms (DRESS). 2 、 10 Due to these concerns, daclizumab was withdrawn from the market in Europe and the US in 2018. 10

Reasons for Side Effects

Daclizumab works by suppressing the immune system, which can lead to various side effects. 9 、 8 This suppression weakens the body’s ability to fight infections, and can also increase the risk of developing new autoimmune diseases. 9 、 8

General Side Effects

Infections

Daclizumab can increase the risk of infections due to its immunosuppressive effects. 9 、 8 It’s important to be vigilant about hygiene and contact your doctor immediately if you develop any signs of infection.

Severe Inflammatory Brain Disease

Cases of severe inflammatory brain disease, some with fatal outcomes, have been reported in patients treated with daclizumab. 10 、 2 This is a serious concern and immediate medical attention is crucial.

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

DRESS is a severe adverse drug reaction that involves skin rashes, fever, swollen lymph nodes, and liver dysfunction. 2 DRESS is a serious condition and requires prompt diagnosis and treatment.

Side Effects Management

Infections

To minimize the risk of infections, maintaining good hygiene practices like hand washing and avoiding close contact with sick individuals is crucial. 9 Regular medical check-ups are important to detect any infections early on.

Severe Inflammatory Brain Disease

Early recognition and treatment of severe inflammatory brain disease are critical due to its potential life-threatening nature. 10 、 2 Regular monitoring and prompt medical attention are essential.

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

If you experience any signs of DRESS, like skin rash, fever, or swollen lymph nodes, seek medical advice immediately. Early diagnosis and treatment are essential for managing DRESS effectively. 2

Comparison Between Studies

Commonalities Between Studies

Studies have consistently shown that daclizumab can effectively treat certain conditions, such as uveitis. 8 However, these studies have also consistently highlighted the risk of serious adverse effects, including severe inflammatory brain disease and DRESS. 2 、 10

Differences Between Studies

Studies have varied in their findings regarding the specific types of side effects, their frequency, and their severity. 9 、 8 、 2 、 10 This highlights the need for further research to understand the full spectrum of risks associated with daclizumab.

Cautions Regarding Application in Real Life

Daclizumab is no longer available on the market due to the serious safety concerns. 10 If you are considering any treatment for MS or other conditions, consult with a qualified healthcare professional.

Limitations of Current Research

While research has shed light on daclizumab’s potential benefits and risks, further research is needed to fully understand its long-term safety and effectiveness. 9 、 8 、 2 、 10

Future Directions for Research

Further research is crucial to understand the long-term impact of daclizumab on the body and to explore potential strategies for managing its side effects. 9 、 8 、 2 、 10 Future research should also focus on identifying individuals who may be at higher risk of developing specific side effects.

Conclusion

Daclizumab was a promising treatment option for relapsing MS, but it was withdrawn from the market due to serious safety concerns. 10 It's important to stay informed about the latest developments in MS treatment and to discuss any potential risks and benefits with your doctor before making decisions about your healthcare.

Literature analysis of 10 papers
Positive Content
8
Neutral Content
1
Negative Content
1
Article Type
2
0
0
5
9
1.

Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement.

Author: MahrleG, SchulzeH J, FärberL, WeidingerG, SteiglederG K

Nail and joint improvement
Psoriasis treatment
Cyclosporine side effects
Relapse risk

Low-dose short-term cyclosporine therapy was highly effective and well tolerated for psoriasis, compared to etretinate. Remission was better preserved by tapering the drug than by discontinuing treatment abruptly.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy.

Author: RauerSebastian, StorkLidia, UrbachHorst, StathiAngeliki, MarxAnna, SüßPatrick, PrinzMarco, BrückWolfgang, MetzImke

DRESS
Neurologic deterioration

Two women with multiple sclerosis (MS) developed severe neurologic deterioration and a drug reaction with eosinophilia and systemic symptoms (DRESS) after treatment with daclizumab.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

An update on new and emerging therapies for relapsing-remitting multiple sclerosis.

Author: Weinstock-GuttmanBianca

Improved adherence
MS treatment
Oral administration
Progressive multifocal leukoencephalopathy
Side effects

Disease-modifying therapies (DMTs) have been used for over a decade to treat relapsing-remitting multiple sclerosis (RRMS). While first-line DMTs have shown only partial benefits and often have inadequate patient adherence, newer DMTs offer more efficacious treatment, more favorable methods of administration, and lower infusion frequencies, which may improve adherence and clinical outcomes.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

6.

Emerging therapies in relapsing-remitting multiple sclerosis.

Author: MarriottJames J, O'ConnorPaul W

Convenience
RRMS treatment
Fatal complications
Side effects

This study reviewed the current and future of disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS). The researchers highlighted the need to weigh the convenience of oral DMTs against the relative inconvenience but long-term safety of current first-line injectable therapies.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

7.

Therapeutic monoclonal antibodies in ophthalmology.

Author: RodriguesEduardo B, FarahMichel E, MaiaMaurício, PenhaFernando M, RegatieriCaio, MeloGustavo B, PinheiroMarcelo M, ZanettiCarlos R

Control inflammation
Control neovascularization
Treat angiogenic diseases
Treat inflammatory diseases
Systemic complications

Monoclonal antibodies (mAbs) are used in ophthalmology to treat various diseases with high specificity. Bevacizumab and ranibizumab (anti-VEGF), infliximab, etanercept, and adalimumab (anti-TNF) are FDA-approved mAbs for angiogenic and inflammatory ocular diseases. Other mAbs show promising results for ocular lymphoma or inflammation, and their role in ophthalmology will be determined by future clinical trials.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.

Author: NussenblattRobert B, ThompsonDarby J S, LiZhuqing, ChanChi Chao, PetersonJan S, RobinsonRandy R, ShamesRichard S, NagarajanSudha, TangMeina Tao, MailmanMichelle, VelezGisela, RoyChandra, Levy-ClarkeGrace A, SuhlerEric B, DjalilianAli, SenHatice Nida, Al-KhatibShadi, UrseaRoxana, SrivastavaSunil, BamjiAllison, MellowSusan, SranPushpa, WaldmannThomas A, BuggageRonald R

Treat severe uveitis

Long-term daclizumab therapy, an anti-IL-2 receptor alpha treatment, was found to be effective in treating severe uveitis in lieu of standard immunosuppression. Subcutaneous daclizumab administration was also found to be a viable treatment strategy.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

9.

[Antibodies and immunomodulation].

Author: BerthouxF

This abstract reviewed the efficacy of immunosuppressor induction agents, including daclizumab, basiliximab, and efalizumab, compared with anti-lymphocyte globulins and anti-OKT3 agents.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : French

10.

Management of MS Patients Treated With Daclizumab - a Case Series of 267 Patients.

Author: RommerPaulus S, BergerKlaus, EllenbergerDavid, FneishFiras, SimbrichAlexandra, StahmannAlexander, ZettlUwe K

Multiple sclerosis treatment
Brain inflammation

This study examines the therapy management of patients who received daclizumab, a drug that was previously used to treat multiple sclerosis (MS), after it was withdrawn from the market due to safety concerns. The study found that most patients switched to other treatments shortly after discontinuing daclizumab.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.